Author Archives for Nathalie Dubois

RenaSci recruits new head of intravenous self-administration group

June 30, 2020 9:30 am Published by Leave your thoughts

RenaSci has appointed Angela Batman as head of department of its intravenous self-administration (IVSA) group. She joins from Covance, where she was Manager of Safety Pharmacology. Angela studied pharmacology at the University of Sheffield. During her PhD at the Medical College of Virginia in the US, she worked with renowned behavioural pharmacologist Patrick Beardsley, one of the key figures in the abuse field. Her project focused on models for a wide range of common drugs...


RenaSci bolsters CNS team

June 24, 2020 9:00 am Published by Leave your thoughts

RenaSci has recruited Jane Cooper as a project leader in the CNS group. She joins from Eli Lilly, where she was most recently In Vivo Team Leader. Jane studied biochemistry at the University of Bristol, followed by an MSc in Advanced Neuropharmacology. This included her introduction to the then-new technique of microdialysis, on which she has built her career. Microdialysis is a powerful method that allows neurotransmitters to be monitored within the extracellular environment. Her...


Sygnature expands capabilities with acquisition of Alderley Oncology

June 3, 2020 1:20 pm Published by Leave your thoughts

Great news from our parent company Sygnature Discovery, we’re further strengthening our oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for cancer drug discovery. The acquisition will add significant in-house expertise at Sygnature in the design, conduct and interpretation of pivotal oncology in vivo pharmacology experiments that help identify promising pre-clinical candidates. These assessments also help define the path...


Binge eating disorder – getting the preclinical models right

May 27, 2020 12:05 pm Published by Leave your thoughts

Binge eating disorder is the most common eating disorder and is recognised as a mental health condition. While it can lead to overeating, the issue is more about a loss of impulse control. Treating this psychiatric illness, rather than merely the symptoms, is key. When those with the disorder open a cupboard and spot a packet of stockpiled cookies before they know it, they’ll have eaten a whole packet. It’s not so much that they’re...


Sygnature Group adds pharmacology expertise to BD team with recruitment of Dr David Loczenski

May 22, 2020 9:30 am Published by Leave your thoughts

Dr David Loczenski has been appointed as Business Development Manager to promote the in vivo pharmacology and consultancy services offered by RenaSci. David takes on the business development role after working for 2 years at RenaSci as a project leader within the metabolic disease group and has extensive in vivo pharmacology expertise with a specific edge in the field of obesity, Non-alcoholic fatty liver disease (NAFLD), insulin resistance and age-associated loss of muscle mass (sarcopenia)....


Key Appointments and Retirements at RenaSci

April 1, 2020 10:45 am Published by Leave your thoughts

As RenaSci moves toward even fuller integration with our colleagues at Sygnature, we’re pleased to announce that from 1st of April 2020, Dr Steve Vickers takes on the role of Deputy Director, RenaSci, and Dr Helen Rowley becomes Vice-President, Neuroscience. Both are widely acknowledged as experienced and highly capable scientific leaders and experts in their respective fields, both within RenaSci and across the broader in vivo / drug discovery scientific community. Steve and Helen will...


COVID-19 – Update

March 25, 2020 11:25 am Published by Leave your thoughts

Update from Sygnature Group following the PM’s announcement Following the announcement from Boris Johnson, the Prime Minister of the United Kingdom on the evening of Monday 23rd March 2020 we felt it would be helpful to give an update from Sygnature Group, comprising Sygnature Discovery and RenaSci. In the PM’s statement, the guidance specifies that people will only be allowed to leave their home for very limited purposes, including travelling to and from work where this...


Kidney disease – A seamless in vitroex vivoin vivo process

March 25, 2020 9:00 am Published by Leave your thoughts

Where are we in terms of preclinical testing? For a disease that will affect 10% of adults, chronic kidney disease (CKD) is remarkably under-diagnosed. As many as 9 out of 10 of those affected are unaware of their condition as in the early stages, there may be no obvious symptoms. In many cases CKD is diagnosed only when a routine blood or urine test is carried out. However, mostly it’s only when people start feeling...


COVID-19 and business continuity

March 17, 2020 9:23 am Published by Leave your thoughts

This article outlines a message from Simon Hirst, CEO and Founder of Sygnature Group. I wanted to tell you about the measures that Sygnature Group, comprising Sygnature Discovery and RenaSci, is implementing relating to the COVID-19 outbreak to ensure the business continues uninterrupted. As a company which has always invested significantly in our informatics and IT infrastructure, Sygnature is well prepared to manage modern teams and flexible working.  As such we feel that we are...


experimental

NASH: towards predictive non-invasive tests

March 5, 2020 10:10 am Published by Leave your thoughts

Are non-invasive tests the solution to accelerate the development of a marketable treatment for the growing challenge of NASH?  RenaSci’s Dr Katie Headland shares her thoughts on the best way forward for the preclinical efforts to fight this silent killer. Non-alcoholic steatohepatitis, or NASH, has had an explosion of interest due to the growing impact on world health. In the United States alone the number of patients with NASH is projected to expand from ~16...